MX2020013291A - Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis. - Google Patents
Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.Info
- Publication number
- MX2020013291A MX2020013291A MX2020013291A MX2020013291A MX2020013291A MX 2020013291 A MX2020013291 A MX 2020013291A MX 2020013291 A MX2020013291 A MX 2020013291A MX 2020013291 A MX2020013291 A MX 2020013291A MX 2020013291 A MX2020013291 A MX 2020013291A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- fibrosis
- alkoxy
- treatment
- receptor antagonists
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract 2
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract 2
- 125000004076 pyridyl group Chemical class 0.000 title abstract 2
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a derivados de piridinilo de Fórmula (I) (Ver Fórmula (I) en donde R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m y n son como se describe en la descripción, su preparación, sus sales farmacéuticamente aceptables y su uso como productos farmacéuticos, las composiciones farmacéuticas que contienen uno o más compuestos de Fórmula (I), y especialmente su uso como moduladores del receptor LPA1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018065016 | 2018-06-07 | ||
| PCT/EP2019/064690 WO2019234115A1 (en) | 2018-06-07 | 2019-06-05 | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013291A true MX2020013291A (es) | 2021-04-29 |
Family
ID=66912779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013291A MX2020013291A (es) | 2018-06-07 | 2019-06-05 | Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210246116A1 (es) |
| EP (1) | EP3802517B1 (es) |
| JP (1) | JP7386183B2 (es) |
| KR (1) | KR20210018900A (es) |
| CN (1) | CN112236424B (es) |
| AU (1) | AU2019282274A1 (es) |
| BR (1) | BR112020024879A2 (es) |
| CA (1) | CA3102683A1 (es) |
| DK (1) | DK3802517T3 (es) |
| EA (1) | EA202092955A1 (es) |
| ES (1) | ES2940695T3 (es) |
| FI (1) | FI3802517T3 (es) |
| HR (1) | HRP20230243T1 (es) |
| HU (1) | HUE061559T2 (es) |
| LT (1) | LT3802517T (es) |
| MX (1) | MX2020013291A (es) |
| PL (1) | PL3802517T3 (es) |
| PT (1) | PT3802517T (es) |
| RS (1) | RS63990B1 (es) |
| SI (1) | SI3802517T1 (es) |
| TW (1) | TW202016090A (es) |
| WO (1) | WO2019234115A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119162A1 (es) * | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| EP4069227A1 (en) | 2019-12-04 | 2022-10-12 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| FI20225388A1 (en) * | 2022-05-05 | 2023-11-06 | Equinorm Ltd | New heterocyclic compounds, preparation methods and their uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| WO2002062389A1 (fr) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| WO2005037269A1 (ja) | 2003-10-21 | 2005-04-28 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピペリジン誘導体 |
| WO2005049605A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Antibacterial aminoquinazolidinedione derivatives |
| WO2007023768A1 (ja) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体（３） |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| US8258135B2 (en) | 2007-10-18 | 2012-09-04 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| MX2010011754A (es) | 2008-05-05 | 2010-12-06 | Sanofi Aventis | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos. |
| CA2735361A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| RU2563639C2 (ru) * | 2009-09-25 | 2015-09-20 | Астеллас Фарма Инк. | Замещенные соединения амида |
| CN103270036B (zh) | 2010-08-05 | 2015-11-25 | 佐蒂斯有限责任公司 | 作为抗寄生物剂的异噁唑啉衍生物 |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| SI2683723T1 (sl) | 2011-03-10 | 2016-07-29 | Zoetis Services Llc | Spirociklični izoksazolinski derivati kot antiparazitiki |
| CA2859965A1 (en) | 2011-12-21 | 2013-06-27 | Ardelyx, Inc. | Non-systemic tgr5 agonists |
| AU2014244183A1 (en) * | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
-
2019
- 2019-06-05 HU HUE19731163A patent/HUE061559T2/hu unknown
- 2019-06-05 PL PL19731163.2T patent/PL3802517T3/pl unknown
- 2019-06-05 EP EP19731163.2A patent/EP3802517B1/en active Active
- 2019-06-05 PT PT197311632T patent/PT3802517T/pt unknown
- 2019-06-05 CN CN201980036967.6A patent/CN112236424B/zh active Active
- 2019-06-05 RS RS20230148A patent/RS63990B1/sr unknown
- 2019-06-05 SI SI201930472T patent/SI3802517T1/sl unknown
- 2019-06-05 US US16/972,878 patent/US20210246116A1/en active Pending
- 2019-06-05 EA EA202092955A patent/EA202092955A1/ru unknown
- 2019-06-05 FI FIEP19731163.2T patent/FI3802517T3/fi active
- 2019-06-05 ES ES19731163T patent/ES2940695T3/es active Active
- 2019-06-05 JP JP2020567808A patent/JP7386183B2/ja active Active
- 2019-06-05 AU AU2019282274A patent/AU2019282274A1/en active Pending
- 2019-06-05 MX MX2020013291A patent/MX2020013291A/es unknown
- 2019-06-05 TW TW108119605A patent/TW202016090A/zh unknown
- 2019-06-05 HR HRP20230243TT patent/HRP20230243T1/hr unknown
- 2019-06-05 LT LTEPPCT/EP2019/064690T patent/LT3802517T/lt unknown
- 2019-06-05 BR BR112020024879-7A patent/BR112020024879A2/pt unknown
- 2019-06-05 KR KR1020217000125A patent/KR20210018900A/ko unknown
- 2019-06-05 WO PCT/EP2019/064690 patent/WO2019234115A1/en unknown
- 2019-06-05 DK DK19731163.2T patent/DK3802517T3/da active
- 2019-06-05 CA CA3102683A patent/CA3102683A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210018900A (ko) | 2021-02-18 |
| AU2019282274A1 (en) | 2021-01-28 |
| EP3802517A1 (en) | 2021-04-14 |
| JP2021527046A (ja) | 2021-10-11 |
| SI3802517T1 (sl) | 2023-04-28 |
| LT3802517T (lt) | 2023-03-10 |
| HRP20230243T1 (hr) | 2023-04-14 |
| EA202092955A1 (ru) | 2021-04-08 |
| FI3802517T3 (fi) | 2023-03-23 |
| HUE061559T2 (hu) | 2023-07-28 |
| EP3802517B1 (en) | 2022-12-21 |
| WO2019234115A1 (en) | 2019-12-12 |
| PT3802517T (pt) | 2023-03-20 |
| JP7386183B2 (ja) | 2023-11-24 |
| RS63990B1 (sr) | 2023-03-31 |
| DK3802517T3 (da) | 2023-03-13 |
| BR112020024879A2 (pt) | 2021-03-09 |
| CN112236424B (zh) | 2024-03-15 |
| PL3802517T3 (pl) | 2023-05-22 |
| CN112236424A (zh) | 2021-01-15 |
| CA3102683A1 (en) | 2019-12-12 |
| TW202016090A (zh) | 2020-05-01 |
| US20210246116A1 (en) | 2021-08-12 |
| ES2940695T3 (es) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| MX2021004000A (es) | Derivados de piperidina. | |
| PH12019502562A1 (en) | N-substituted indole derivatives | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| MY195888A (en) | N-Substituted Indole Derivatives As Pge2 Receptor Modulators | |
| MX2020013291A (es) | Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis. | |
| MY152486A (en) | Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators | |
| MX2021004940A (es) | Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos. | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| MX2022006736A (es) | Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas. | |
| MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
| PH12019501724A1 (en) | Estrogen receptor modulators | |
| CR20210284A (es) | Pirazoles como modulares de hemoglobina | |
| NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| MX2022016263A (es) | Derivados de ciclobutil-urea. | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| MX2021015727A (es) | Derivados de piridin-3-ilo. | |
| MX2022004215A (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4. | |
| CR20210173A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
| NZ775905A (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators |